Literature DB >> 17855633

A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification.

Dorothee Mueller1, Christian Bach, Deniz Zeisig, Maria-Paz Garcia-Cuellar, Sara Monroe, Arun Sreekumar, Rong Zhou, Alexey Nesvizhskii, Arul Chinnaiyan, Jay L Hess, Robert K Slany.   

Abstract

Chimeric proteins joining the histone methyltransferase MLL with various fusion partners trigger distinctive lymphoid and myeloid leukemias. Here, we immunopurified proteins associated with ENL, a protein commonly fused to MLL. Identification of these ENL-associated proteins (EAPs) by mass spectrometry revealed enzymes with a known role in transcriptional elongation (RNA polymerase II C-terminal domain kinase [RNAPolII CTD] positive transcription elongation factor b [pTEFb]), and in chromatin modification (histone-H3 methyltransferase DOT1L) as well as other frequent MLL partners (AF4, AF5q31, and LAF4), and polycomb group members (RING1, CBX8, and BCoR). The composition of EAP was further verified by coimmunoprecipitation, 2-hybrid analysis, pull-down, and colocalization experiments. Purified EAP showed a histone H3 lysine 79-specific methylase activity, displayed a robust RNAPolII CTD kinase function, and counteracted the effect of the pTEFb inhibitor 5,6-dichloro-benzimidazole-riboside. In vivo, an ENL knock-down diminished genome-wide as well as gene-specific H3K79 dimethylation, reduced global run-on elongation, and inhibited transient transcriptional reporter activity. According to structure-function data, DOT1L recruitment was important for transformation by the MLL-ENL fusion derivative. These results suggest a function of ENL in histone modification and transcriptional elongation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17855633      PMCID: PMC2234781          DOI: 10.1182/blood-2007-05-090514

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Probability-based protein identification by searching sequence databases using mass spectrometry data.

Authors:  D N Perkins; D J Pappin; D M Creasy; J S Cottrell
Journal:  Electrophoresis       Date:  1999-12       Impact factor: 3.535

2.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search.

Authors:  Andrew Keller; Alexey I Nesvizhskii; Eugene Kolker; Ruedi Aebersold
Journal:  Anal Chem       Date:  2002-10-15       Impact factor: 6.986

3.  MCEF, the newest member of the AF4 family of transcription factors involved in leukemia, is a positive transcription elongation factor-b-associated protein.

Authors:  Mario Clemente Estable; Mojgan H Naghavi; Hiroyuki Kato; Hua Xiao; Jun Qin; Anders Vahlne; Robert G Roeder
Journal:  J Biomed Sci       Date:  2002 May-Jun       Impact factor: 8.410

4.  The polycomb protein MPc3 interacts with AF9, an MLL fusion partner in t(9;11)(p22;q23) acute leukemias.

Authors:  C S Hemenway; A C de Erkenez; G C Gould
Journal:  Oncogene       Date:  2001-06-28       Impact factor: 9.867

5.  HPC3 is a new human polycomb orthologue that interacts and associates with RING1 and Bmi1 and has transcriptional repression properties.

Authors:  J I Bárdos; A J Saurin; C Tissot; E Duprez; P S Freemont
Journal:  J Biol Chem       Date:  2000-09-15       Impact factor: 5.157

6.  The ENL moiety of the childhood leukemia-associated MLL-ENL oncoprotein recruits human Polycomb 3.

Authors:  M P García-Cuéllar; O Zilles; S A Schreiner; M Birke; T H Winkler; R K Slany
Journal:  Oncogene       Date:  2001-01-25       Impact factor: 9.867

7.  BCoR, a novel corepressor involved in BCL-6 repression.

Authors:  K D Huynh; W Fischle; E Verdin; V J Bardwell
Journal:  Genes Dev       Date:  2000-07-15       Impact factor: 11.361

8.  Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain.

Authors:  Qin Feng; Hengbin Wang; Huck Hui Ng; Hediye Erdjument-Bromage; Paul Tempst; Kevin Struhl; Yi Zhang
Journal:  Curr Biol       Date:  2002-06-25       Impact factor: 10.834

9.  The leukemia-associated gene Mllt1/ENL: characterization of a murine homolog and demonstration of an essential role in embryonic development.

Authors:  Raymond T Doty; Gary J Vanasse; Christine M Disteche; Dennis M Willerford
Journal:  Blood Cells Mol Dis       Date:  2002 May-Jun       Impact factor: 3.039

10.  The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling.

Authors:  Emmanuelle Bitoun; Peter L Oliver; Kay E Davies
Journal:  Hum Mol Genet       Date:  2006-11-29       Impact factor: 6.150

View more
  194 in total

Review 1.  The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis.

Authors:  Ali Shilatifard
Journal:  Annu Rev Biochem       Date:  2012       Impact factor: 23.643

2.  Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?

Authors:  Tim C P Somervaille; Michael L Cleary
Journal:  Int J Hematol       Date:  2010-05-08       Impact factor: 2.490

3.  Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis.

Authors:  Man Mohan; Chengqi Lin; Erin Guest; Ali Shilatifard
Journal:  Nat Rev Cancer       Date:  2010-09-16       Impact factor: 60.716

4.  Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6.

Authors:  Michaela Liedtke; Paul M Ayton; Tim C P Somervaille; Kevin S Smith; Michael L Cleary
Journal:  Blood       Date:  2010-04-15       Impact factor: 22.113

5.  The eleven-nineteen lysine-rich leukemia gene (ELL2) influences the histone H3 protein modifications accompanying the shift to secretory immunoglobulin heavy chain mRNA production.

Authors:  Christine Milcarek; Michael Albring; Creityeka Langer; Kyung Soo Park
Journal:  J Biol Chem       Date:  2011-08-09       Impact factor: 5.157

Review 6.  BET domain co-regulators in obesity, inflammation and cancer.

Authors:  Anna C Belkina; Gerald V Denis
Journal:  Nat Rev Cancer       Date:  2012-06-22       Impact factor: 60.716

Review 7.  The upstreams and downstreams of H3K79 methylation by DOT1L.

Authors:  Hanneke Vlaming; Fred van Leeuwen
Journal:  Chromosoma       Date:  2016-01-04       Impact factor: 4.316

8.  Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents.

Authors:  Cecily A Bennett; Amanda C Winters; Nisha N Barretto; Charles S Hemenway
Journal:  Leuk Res       Date:  2009-02-20       Impact factor: 3.156

9.  The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.

Authors:  Eytan M Stein; Guillermo Garcia-Manero; David A Rizzieri; Raoul Tibes; Jesus G Berdeja; Michael R Savona; Mojca Jongen-Lavrenic; Jessica K Altman; Blythe Thomson; Stephen J Blakemore; Scott R Daigle; Nigel J Waters; A Benjamin Suttle; Alicia Clawson; Roy Pollock; Andrei Krivtsov; Scott A Armstrong; Jorge DiMartino; Eric Hedrick; Bob Löwenberg; Martin S Tallman
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

10.  Proteomic approaches for cancer epigenetics research.

Authors:  Dylan M Marchione; Benjamin A Garcia; John Wojcik
Journal:  Expert Rev Proteomics       Date:  2018-11-27       Impact factor: 3.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.